Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)

被引：0
|
作者：
Chen, Jinzhang
Zang, Mengya
Pang, Huajin
Li, Chuanjiang
Zhao, Jianbo
Guo, Yabing
Hou, Jinlin
机构：
[1] Southern Med Univ, Hepatol Unit, Nanfang Hosp, Guangzhou, Peoples R China
[2] Southern Med Univ, Dept Infect Dis, Nanfang Hosp, Guangzhou, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Ke, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16128
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CAMRELIZUMAB COMBINED WITH LENVATINIB AND RALOX-HAIC FOR HEPATOCELLULAR CARCINOMA (HCC) IN BCLC STAGE B AND C: A PROSPECTIVE, SINGLE-ARM TRIAL (CAL ERA STUDY)
    Zang, Mengya
    Li, Yuanfeng
    Yuan, Guosheng
    Li, Qi
    Hu, Xiaoyun
    Li, Wenli
    Li, Chuanjiang
    Pang, Huajin
    HEPATOLOGY, 2024, 80 : S1967 - S1968
  • [2] Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Zang, M.
    Li, Q.
    Pang, H.
    Hu, X.
    Li, R.
    Yuan, G.
    Li, W.
    Guo, Y.
    Chen, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S874 - S874
  • [3] Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
    Zhang, T-Q.
    Zuo, M-X.
    Geng, Z-J.
    Huang, Z-L.
    Li, J-B.
    Wu, P-H.
    Gu, Y-K.
    ANNALS OF ONCOLOGY, 2021, 32 : S825 - S825
  • [4] Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).
    Gu, Yang-Kui
    Zhang, Tian-Qi
    Zuo, Meng-Xuan
    Geng, Zhi-Jun
    Li, Ji-Bin
    Huang, Zi-Lin
    Wu, Pei-Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial
    Zhou, X.
    Zhu, H.
    Gao, H.
    Niu, Z.
    Liu, M.
    Wang, H.
    Kong, X.
    Ma, C.
    Yang, F.
    Hao, Y.
    Zhang, S.
    Lu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1489 - S1489
  • [6] Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study
    Zhang, Zhibo
    Yan, Maolin
    Chen, Yufeng
    Wu, Xukun
    Yang, Lanfang
    Yin, Zhengyu
    Lu, Hao
    Zeng, Yongyi
    Zhang, Hui
    Huang, Jingyao
    Chen, Jiafei
    Wang, Liang
    Chen, Zhongwu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu Yunxiuxiu
    Wang, Jie
    Zhong, Guoping
    Xiao, Zhiyu
    Zhou, Zhenyu
    Ye, Congting
    Li, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial
    Pan, Long
    Sun, Ruirui
    He, Qiang
    Zhou, Yin
    Li, Jiachu
    Gou, Yang
    Wu, Chenrui
    Fu, Zixuan
    Zhao, Yaowu
    He, Qin
    Huang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial
    Liu, Dongming
    Mu, Han
    Liu, Changfu
    Zhang, Weihao
    Cui, Yunlong
    Wu, Qiang
    Zhu, Xiaolin
    Fang, Feng
    Zhang, Wei
    Xing, Wenge
    Li, Qiang
    Song, Tianqiang
    Lu, Wei
    Li, Huikai
    NEOPLASMA, 2023, 70 (06) : 811 - 818
  • [10] FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: A single-arm, phase II study
    Wang, Z.
    Zheng, C.
    Liang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1483
12345